Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome

Journal of Thrombosis and Thrombolysis

Volumn 31, Issue 2, 2011, Pages 146-153

  Becker, Richard C ^a,b   Mahaffey, Kenneth W ^a   Yang, Hongqiu ^b   Marian, A J ^c   Furman, Mark I ^d   Michael Lincoff, A ^e   Hazen, Stanley L ^e   Petersen, John L ^f   Reist, Craig J ^a   Kleiman, Neal S ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d South Shore Hospital   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f NONE   (United States)

Author keywords

Antithrombin; Factor Xa inhibition; Heparin compounds; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 10A; CD40 LIGAND; ENOXAPARIN; HEPARIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE FACTOR PATHWAY INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLOOD CLOTTING; DISEASE MARKER; DRUG EFFECT; FEMALE; HIGH RISK PATIENT; HUMAN; IN VIVO STUDY; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE ACTIVATION; VASCULAR ENDOTHELIUM;

ACUTE CORONARY SYNDROME; AGED; BIOLOGICAL MARKERS; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD PLATELETS; CD40 LIGAND; ENOXAPARIN; FACTOR XA; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET ACTIVATION; RISK FACTORS;

EID: 79951726144     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-010-0532-y     Document Type: Article

References (41)

1. W Koenig N Khuseyinova 2007 Biomarkers of atherosclerotic plaque instability and rupture Arterioscler Thromb Vasc Biol 27 1 15 26 1:CAS:528:DC%2BD28XhtlSrsb7I 10.1161/01.ATV.0000251503.35795.4f 17082488 (Pubitemid 46360377)
2. P Libby PM Ridker A Maseri 2002 Inflammation and atherosclerosis Circulation 105 9 1135 1143 1:CAS:528:DC%2BD38XislWhu7k%3D 10.1161/hc0902.104353 11877368 (Pubitemid 34212626)
3. M Namba, et al. 2007 Circulating platelet-derived microparticles are associated with atherothrombotic events: a marker for vulnerable blood Arterioscler Thromb Vasc Biol 27 1 255 256 1:CAS:528:DC%2BD2sXhtVygsrs%3D 10.1161/01.ATV.0000252064.97632.2c 17185627 (Pubitemid 46360410)
4. S Waxman F Ishibashi JE Muller 2006 Detection and treatment of vulnerable plaques and vulnerable patients: novel approaches to prevention of coronary events Circulation 114 22 2390 2411 10.1161/CIRCULATIONAHA.105.540013 17130356 (Pubitemid 44848285)
5. JL Petersen, et al. 2004 Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library Am Heart J 148 269 276 1:CAS:528:DC%2BD2cXmslOhsLw%3D 10.1016/j.ahj.2004.03.022 15308996 (Pubitemid 39092791)
6. JJ Ferguson, et al. 2004 Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial J Am Med Assoc 292 1 45 54 1:CAS:528:DC%2BD2cXls1elsrg%3D 10.1001/jama.292.1.45 (Pubitemid 38923793)
7. E Falk 2006 Pathogenesis of atherosclerosis J Am Coll Cardiol 47 8 Suppl C7 C12 1:CAS:528:DC%2BD28XksVKmtrs%3D 10.1016/j.jacc.2005.09.068 16631513
8. RC Becker, et al. 1996 Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction. Thrombolysis in myocardial ischemia III B investigators Am Heart J 131 3 421 433 1:STN:280:DyaK287otlehug%3D%3D 10.1016/S0002-8703(96)90519-0 8604620 (Pubitemid 26086593)
9. R Wagenvoord, et al. 2008 Linear diffusion of thrombin and factor Xa along the heparin molecule explains the effects of extended heparin chain lengths Thromb Res 122 2 237 245 1:CAS:528:DC%2BD1cXmsFyntLY%3D 10.1016/j.thromres.2007.10.008 18045667 (Pubitemid 351754922)
10. RC Becker, et al. 2002 Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes Am Heart J 143 753 759 1:CAS:528:DC%2BD38XltFartL0%3D 10.1067/mhj.2002.120774 12040334 (Pubitemid 34595330)
11. G Montalescot, et al. 2006 Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention N Engl J Med 355 10 1006 1017 1:CAS:528:DC%2BD28XpsFKmtbY%3D 10.1056/NEJMoa052711 16957147 (Pubitemid 44343544)
12. G Montalescot, et al. 2008 Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial Eur Heart J 29 4 462 471 1:CAS:528:DC%2BD1cXjs1ensLc%3D 10.1093/eurheartj/ehn008 18276619 (Pubitemid 351264194)
13. GA Allen, et al. 2004 Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system J Thromb Haemost 2 3 402 413 1:CAS:528:DC%2BD2cXktVGms74%3D 10.1111/j.1538-7933.2003.00617.x 15009455 (Pubitemid 40185650)
14. CL Kempton, et al. 2005 Platelet heterogeneity: variation in coagulation complexes on platelet subpopulations Arterioscler Thromb Vasc Biol 25 4 861 866 1:CAS:528:DC%2BD2MXitlOmsLg%3D 10.1161/01.ATV.0000155987.26583.9b 15653564 (Pubitemid 40463882)
15. G Cirino, et al. 1997 Factor Xa as an interface between coagulation and inflammation. Molecular mimicry of factor Xa association with effector cell protease receptor-1 induces acute inflammation in vivo J Clin Investig 99 10 2446 2451 1:CAS:528:DyaK2sXjsVGqtrY%3D 10.1172/JCI119428 9153288 (Pubitemid 27227723)
16. V Daubie, et al. 2006 Factor Xa and thrombin evoke additive calcium and proinflammatory responses in endothelial cells subjected to coagulation Biochim Biophys Acta 1763 8 860 869 1:CAS:528:DC%2BD28XotlWhsLY%3D 10.1016/j.bbamcr. 2006.04.010 16765466 (Pubitemid 44205273)
17. SI Rapaport LV Rao 1992 Initiation and regulation of tissue factor-dependent blood coagulation Arterioscler Thromb 12 10 1111 1121 1:CAS:528:DyaK3sXls1Ogug%3D%3D 1390583
18. GJ Broze Jr 1992 The role of tissue factor pathway inhibitor in a revised coagulation cascade Semin Hematol 29 3 159 169 1:CAS:528:DyaK38XlvVylu7w%3D 1641662
19. MS Bajaj, et al. 1999 Transcriptional expression of tissue factor pathway inhibitor, thrombomodulin and von Willebrand factor in normal human tissues Thromb Haemost 82 3 1047 1052 1:CAS:528:DyaK1MXmtF2gsLc%3D 10494762 (Pubitemid 29419717)
20. P Golino, et al. 2003 Involvement of tissue factor pathway inhibitor in the coronary circulation of patients with acute coronary syndromes Circulation 108 23 2864 2869 1:CAS:528:DC%2BD3sXptlyjtrg%3D 10.1161/01.CIR.0000105900.21445. 3D 14656922 (Pubitemid 37517813)
21. Y Li, et al. 2002 Comparative effects of unfractionated heparin and low molecular weight heparin on vascular endothelial cell tissue factor pathway inhibitor release: a model for assessing intrinsic thromboresistance J Thromb Thrombolysis 14 2 123 129 1:CAS:528:DC%2BD38XnsFyrtrg%3D 10.1023/A:1023280811804 12714831 (Pubitemid 36559678)
22. RC Becker, et al. 2004 Vascular endothelial tissue factor pathway inhibitor kinetics in culture following exposure to DX-9065a-a selective and direct factor Xa inhibitor J Thromb Thrombolysis 18 3 193 197 1:CAS:528:DC%2BD2MXivFOgtro%3D 10.1007/s11239-005-0345-6 15815881 (Pubitemid 40558035)
23. V Henn, et al. 1998 CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells Nature 391 6667 591 594 1:CAS:528:DyaK1cXhtVSlsb8%3D 10.1038/35393 9468137 (Pubitemid 28157601)
24. AD Michelson, et al. 2001 Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction Circulation 104 13 1533 1537 1:CAS:528: DC%2BD3MXnvVeqtbs%3D 10.1161/hc3801.095588 11571248 (Pubitemid 32917347)
25. MI Furman, et al. 2001 Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction J Am Coll Cardiol 38 4 1002 1006 1:STN:280:DC%2BD3Mrjs1Whtg%3D%3D 10.1016/S0735-1097(01)01485-1 11583872 (Pubitemid 32912702)
26. R Nakamura, et al. 2006 Less pronounced enhancement of thrombin-dependent inactivation of plasminogen activator inhibitor type 1 by low molecular weight heparin compared with unfractionated heparin Thromb Haemost 95 4 637 642 1:CAS:528:DC%2BD28XksFWqs74%3D 16601834
27. EP Bianchini RN Pike BF Le Bonniec 2004 The elusive role of the potential factor X cation-binding exosite-1 in substrate and inhibitor interactions J Biol Chem 279 5 3671 3679 1:CAS:528:DC%2BD2cXmtlCktA%3D%3D 10.1074/jbc. M309691200 14583605 (Pubitemid 38140609)
28. RC Becker, et al. 1994 The clinical use of flow cytometry for assessing platelet activation in acute coronary syndromes. TIMI-III thrombosis and anticoagulation group Coron Artery Dis 5 4 339 345 1:STN:280: DyaK2czhvFGntQ%3D%3D 10.1097/00019501-199404000-00010 7519107 (Pubitemid 24151528)
29. H Brogren, et al. 2004 Platelets synthesize large amounts of active plasminogen activator inhibitor 1 Blood 104 13 3943 3948 1:CAS:528: DC%2BD2cXhtFaju7rO 10.1182/blood-2004-04-1439 15315974 (Pubitemid 39620142)
30. G Montalescot, et al. 2003 Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study) Am J Cardiol 91 8 925 930 1:CAS:528: DC%2BD3sXislentbY%3D 10.1016/S0002-9149(03)00105-X 12686329 (Pubitemid 36398522)
31. G Montalescot, et al. 2000 Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina J Am Coll Cardiol 36 1 110 114 1:CAS:528:DC%2BD3cXlsFGgs7s%3D 10.1016/S0735-1097(00)00695-1 10898421 (Pubitemid 30466120)
32. M Jayachandran 2005 Estrogenic regulation of tissue factor and tissue factor pathway inhibitor in platelets Am J Physiol Heart Circ Physiol 289 5 H1908 H1916 1:CAS:528:DC%2BD2MXht1Cnt7nJ 10.1152/ajpheart.01292.2004 15964915 (Pubitemid 41507339)
33. Z Xiao P Theroux 1998 Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor Circulation 97 3 251 256 1:CAS:528:DyaK1cXptVCrsA%3D%3D 9462526 (Pubitemid 28067310)
34. R Landolfi, et al. 1994 Effects of unfractionated and low molecular weight heparins on platelet thromboxane biosynthesis "in vivo" Thromb Haemost 72 6 942 946 1:CAS:528:DyaK2MXivVygsrg%3D 7740468
35. JP Miletich CM Jackson PW Majerus 1977 Interaction of coagulation factor Xa with human platelets Proc Natl Acad Sci USA 74 9 4033 4036 1:CAS:528:DyaE2sXlvVWls7o%3D 10.1073/pnas.74.9.4033 333455 (Pubitemid 8197769)
36. D Heiden CH Mielke Jr R Rodvien Jr 1977 Impairment by heparin of primary haemostasis and platelet [14C]5-hydroxytryptamine release Br J Haematol 36 3 427 436 1:CAS:528:DyaE2sXlsVGqtrc%3D 10.1111/j.1365-2141.1977.tb00666.x 889712 (Pubitemid 8149941)
37. F Fernandez, et al. 1986 Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect Thromb Res 43 4 491 495 1:CAS:528:DyaL28XltVyiu7Y%3D 10.1016/0049-3848(86)90094-0 3764805 (Pubitemid 16064365)
38. E De Candia R De Cristofaro R Landolfi 1999 Thrombin-induced platelet activation is inhibited by high- and low-molecular-weight heparin Circulation 99 25 3308 3314 10385507 (Pubitemid 29293443)
39. C Heeschen, et al. 2003 Soluble CD40 ligand in acute coronary syndromes N Engl J Med 348 12 1104 1111 1:CAS:528:DC%2BD3sXit1Smtbs%3D 10.1056/NEJMoa022600 12646667 (Pubitemid 36337321)
40. N Konishi K Hiroe M Kawamura 2010 Synergistic effect of a factor Xa inhibitor, TAK-442, and antiplatelet agents on whole blood coagulation and arterial thrombosis in rats Thrombo Res 126 2 124 129 1:CAS:528: DC%2BC3cXpt12ksLo%3D 10.1016/j.thromres.2010.04.005
41. MM Samama, et al. 2010 Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor Thromb Haemost 103 4 815 825 1:CAS:528:DC%2BC3cXls1ansro%3D 20135059